Phaseline

Companies › Beijing Dongfang Biotech

Beijing Dongfang Biotech: clinical trials, targets and expected readouts

1 active drug program in 3 registered trials: 3 Phase 3; Metabolic and endocrine; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
JY09 (1.2mg)
Exendin-4 Fc fusion protein; GLP-1 receptor agonist
GLP1RPhase 3Type 2 Diabetes Mellitus; Type2 Diabetes MellitusNov 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06254014JY09 (1.2mg)Phase 3Type 2 Diabetes MellitusMetabolic and endocrineMay 2026
NCT06257966JY09 (1.2mg)Phase 3Type2 Diabetes MellitusMetabolic and endocrineNov 2026
NCT06257966JY09 (1.2mg)Phase 3Type2 Diabetes MellitusMetabolic and endocrineNov 2026

Targets

GLP1R (1)

Companies with the same targets

Eli Lilly Novo Nordisk Roche Hangzhou Sciwind Biosciences Hangzhou Zhongmei Huadong Pharmaceutical Hanmi Pharmaceutical Company AstraZeneca Amgen Regeneron Pharmaceuticals Green Valley (Shanghai) Pharmaceuticals

Companies built like this

Verdiva Bio Dev Chendu DIAO Pharmaceutical Group Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics Kailera Actimed Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.